Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$44.36 USD
-0.18 (-0.40%)
Updated Sep 10, 2024 03:59 PM ET
After-Market: $44.38 +0.02 (0.05%) 5:12 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.36 USD
-0.18 (-0.40%)
Updated Sep 10, 2024 03:59 PM ET
After-Market: $44.38 +0.02 (0.05%) 5:12 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Amphastar Pharmaceuticals (AMPH) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $47.55, denoting a +0.76% change from the preceding trading day.
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $45.74, moving -0.54% from the previous trading session.
Amphastar Pharmaceuticals (AMPH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amphastar Pharmaceuticals (AMPH) closed at $45.88, marking a +0.81% move from the previous day.
Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $46.04, moving -0.41% from the previous trading session.
Should You Invest in Amphastar (AMPH) Based on Bullish Wall Street Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Amphastar (AMPH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $46.30, moving -0.73% from the previous trading session.
Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why
by Zacks Equity Research
Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
by Zacks Equity Research
Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.
HCA Healthcare (HCA) Rises 24% in a Year: More Room to Run?
by Zacks Equity Research
HCA Healthcare (HCA) is well-poised for growth on the back of improved patient occupancy levels, effective telehealth services suite and solid cash-generating abilities.
Take the Zacks Approach to Beat the Markets: Celsius, Adobe, Curtiss-Wright in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical
by Zacks Equity Research
Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical are part of the Zacks Industry Outlook article.
Is Amphastar (AMPH) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.
Cigna (CI) Unit Ties Up to Offer Digital Health Tool to Clients
by Zacks Equity Research
Cigna's (CI) division, Cigna Healthcare, teams up with Virgin Pulse to make an effective digital health solution available to its clients, who can now improve their well-being.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Dr. Reddy's Laboratories Ltd (RDY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Doctor Reddy's (RDY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 14.04% and 6.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up
by Zacks Equity Research
TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -13.95% and 65.14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.
Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $61.38, moving -0.44% from the previous trading session.
Amphastar Pharmaceuticals (AMPH) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Amphastar (AMPH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Amphastar's (AMPH) revenues in the second quarter of 2023 are expected to have been driven by the sales of its high-margin pharmaceutical products.
Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed at $63.25 in the latest trading session, marking a +1.48% move from the prior day.
The Zacks Analyst Blog Highlights Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations
by Zacks Equity Research
Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations are included in this Analyst Blog.